新天药业控股股东新天智药拟减持不超705万股

Group 1 - The core point of the article is that the controlling shareholder of Xintian Pharmaceutical plans to reduce its stake in the company by selling up to 7.05 million shares, which represents approximately 2.9962% of the total share capital after excluding shares in the repurchase account [1] Group 2 - The planned reduction in shareholding will occur between November 11, 2025, and February 10, 2026, through block trades and centralized bidding [1]